Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice

Journal of Nutritional Biochemistry

Volumn 26, Issue 12, 2015, Pages 1479-1490

  Qosa, Hisham ^a   Mohamed, Loqman A ^a   Batarseh, Yazan S ^a   Alqahtani, Saeed ^a   Ibrahim, Baher ^a   LeVine, Harry ^b   Keller, Jeffrey N ^c   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Amyloid ; Blood brain barrier; Clearance; Extra virgin olive oil; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; EXTRA VIRGIN OLIVE OIL; TAU PROTEIN; AMYLOID; MAPT PROTEIN, MOUSE; OLIVE OIL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; BLOOD BRAIN BARRIER; COGNITION; CONTROLLED STUDY; DISEASE COURSE; HIPPOCAMPUS; MEDITERRANEAN DIET; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VASCULAR AMYLOIDOSIS; ANIMAL; BRAIN; DISEASE MODEL; MALE; METABOLISM; MICROCIRCULATION; TRANSGENIC MOUSE; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; COGNITION; DIET, MEDITERRANEAN; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MICE; MICE, TRANSGENIC; MICROCIRCULATION; OLIVE OIL; TAU PROTEINS;

EID: 84983158340     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.07.022     Document Type: Article

References (62)

1. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010, 9:387-398.
2. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
3. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009, 110:1129-1134.
4. Lehman E.J., Kulnane L.S., Lamb B.T. Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging 2003, 24:645-653.
5. Iqbal K., Liu F., Gong C.X., Alonso Adel C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118:53-69.
6. Scarmeas N., Stern Y., Tang M.X., Mayeux R., Luchsinger J.A. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 2006, 59:912-921.
7. Gu Y., Nieves J.W., Stern Y., Luchsinger J.A., Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 2010, 67:699-706.
8. Scarmeas N., Stern Y., Mayeux R., Manly J.J., Schupf N., Luchsinger J.A. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009, 66:216-225.
9. Tuck K.L., Hayball P.J. Major phenolic compounds in olive oil: metabolism and health effects. J Nutr Biochem 2002, 13:636-644.
10. Salvini S., Sera F., Caruso D., Giovannelli L., Visioli F., Saieva C., et al. Daily consumption of a high-phenol extra-virgin olive oil reduces oxidative DNA damage in postmenopausal women. Br J Nutr 2006, 95:742-751.
11. Malhotra A., Maruthappu M., Stephenson T. Healthy eating: an NHS priority A sure way to improve health outcomes for NHS staff and the public. Postgrad Med J 2014, 90:671-672.
12. Corona G., Spencer J.P., Dessi M.A. Extra virgin olive oil phenolics: absorption, metabolism, and biological activities in the GI tract. Toxicol Ind Health 2009, 25:285-293.
13. Tripoli E., Giammanco M., Tabacchi G., Di Majo D., Giammanco S., La Guardia M. The phenolic compounds of olive oil: structure, biological activity and beneficial effects on human health. Nutr Res Rev 2005, 18:98-112.
14. Cicerale S., Lucas L., Keast R. Biological activities of phenolic compounds present in virgin olive oil. Int J Mol Sci 2010, 11:458-479.
15. Vissers M.N., Zock P.L., Katan M.B. Bioavailability and antioxidant effects of olive oil phenols in humans: a review. Eur J Clin Nutr 2004, 58:955-965.
16. Lopez S., Bermudez B., Montserrat-de la Paz S., Jaramillo S., Varela L.M., Ortega-Gomez A., et al. Membrane composition and dynamics: a target of bioactive virgin olive oil constituents. Biochim Biophys Acta 1838, 2014:1638-1656.
17. Farr S.A., Price T.O., Dominguez L.J., Motisi A., Saiano F., Niehoff M.L., et al. Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers Dis 2012, 28:81-92.
18. Pitozzi V., Jacomelli M., Zaid M., Luceri C., Bigagli E., Lodovici M., et al. Effects of dietary extra-virgin olive oil on behaviour and brain biochemical parameters in ageing rats. Br J Nutr 2010, 103:1674-1683.
19. Pitozzi V., Jacomelli M., Catelan D., Servili M., Taticchi A., Biggeri A., et al. Long-term dietary extra-virgin olive oil rich in polyphenols reverses age-related dysfunctions in motor coordination and contextual memory in mice: role of oxidative stress. Rejuvenation Res 2012, 15:601-612.
20. Abuznait A.H., Qosa H., Busnena B.A., El Sayed K.A., Kaddoumi A. Olive-oil-derived oleocanthal enhances beta-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. ACS Chem Neurosci 2013, 4:973-982.
21. Grossi C., Rigacci S., Ambrosini S., Ed Dami T., Luccarini I., Traini C., et al. The polyphenol oleuropein aglycone protects TgCRND8 mice against Ass plaque pathology. PLoS One 2013, 8:e71702.
22. Luccarini I., Ed Dami T., Grossi C., Rigacci S., Stefani M., Casamenti F. Oleuropein aglycone counteracts Abeta42 toxicity in the rat brain. Neurosci Lett 2014, 558:67-72.
23. Beauchamp G.K., Keast R.S., Morel D., Lin J., Pika J., Han Q., et al. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 2005, 437:45-46.
24. Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 2004, 279:20296-20306.
25. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1:345-347.
26. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248:1124-1126.
27. Grabowski T.J., Cho H.S., Vonsattel J.P., Rebeck G.W., Greenberg S.M. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001, 49:697-705.
28. Pérez-Trujillo M., Gómez-Caravaca A.M., Segura-Carretero A., Fernández-Gutiérrez A., Parella T. Separation and identification of phenolic compounds of extra virgin olive oil from Olea europaea L. by HPLC-DAD-SPE-NMR/MS. Identification of a new diastereoisomer of the aldehydic form of oleuropein aglycone. J Agric Food Chem 2010, 58:9129-9136.
29. Murphy M.P., Beckett T.L., Ding Q., Patel E., Markesbery W.R., St Clair D.K., et al. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 2007, 27:301-311.
30. Qosa H., LeVine H., Keller J.N., Kaddoumi A. Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842, 2014:1806-1815.
31. Ly P.T., Cai F., Song W. Detection of neuritic plaques in Alzheimer's disease mouse model. J Vis Exp 2011, 10.3791/2831.
32. Van Nostrand W.E., Xu F., Rozemuller A.J., Colton C.A. Enhanced capillary amyloid angiopathy-associated pathology in Tg-SwDI mice with deleted nitric oxide synthase 2. Stroke 2010, 41:S135-S138.
33. Qosa H., Abuasal B.S., Romero I.A., Weksler B., Couraud P.O., Keller J.N., et al. Differences in amyloid-beta clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology 2014, 79C:668-678.
34. Kuhnke D., Jedlitschky G., Grube M., Krohn M., Jucker M., Mosyagin I., et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides - implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 2007, 17:347-353.
35. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., et al. Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499.
36. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism?. Nat Med 2000, 6:718-719.
37. Qosa H., Abuznait A.H., Hill R.A., Kaddoumi A. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 2012, 31:151-165.
38. Deacon R. Assessing burrowing, nest construction, and hoarding in mice. J Vis Exp 2012, 10.3791/2607.
39. Deacon R.M. Assessing nest building in mice. Nat Protoc 2006, 1:1117-1119.
40. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001, 7:161-171.
41. Lefebvre P., Benomar Y., Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 2010, 21:676-683.
42. Scarmeas N., Stern Y., Mayeux R., Luchsinger J.A. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 2006, 63:1709-1717.
43. Scarmeas N., Luchsinger J.A., Stern Y., Gu Y., He J., DeCarli C., et al. Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease. Ann Neurol 2011, 69:257-268.
44. Lopez-Miranda J., Perez-Jimenez F., Ros E., De Caterina R., Badimon L., Covas M.I., et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr Metab Cardiovasc Dis 2010, 20:284-294.
45. Monti M.C., Margarucci L., Tosco A., Riccio R., Casapullo A. New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component. Food Funct 2011, 2:423-428.
46. Ramirez-Tortosa M.C., Urbano G., López-Jurado M., Nestares T., Gomez M.C., Mir A., et al. Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in free-living men with peripheral vascular disease. J Nutr 1999, 129:2177-2183.
47. de la Torre-Carbot K., Chávez-Servín J.L., Jaúregui O., Castellote A.I., Lamuela-Raventós R.M., Nurmi T., et al. Elevated circulating LDL phenol levels in men who consumed virgin rather than refined olive oil are associated with less oxidation of plasma LDL. J Nutr 2010, 140:501-508.
48. Pitt J., Roth W., Lacor P., Smith A.B., Blankenship M., Velasco P., et al. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol 2009, 240:189-197.
49. Wang J., Dickson D.W., Trojanowski J.Q., Lee V.M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999, 158:328-337.
50. Benzing W.C., Mufson E.J., Armstrong D.M. Alzheimer's disease-like dystrophic neurites characteristically associated with senile plaques are not found within other neurodegenerative diseases unless amyloid beta-protein deposition is present. Brain Res 1993, 606:10-18.
51. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
52. Knopman D.S. Mediterranean diet and late-life cognitive impairment: a taste of benefit. JAMA 2009, 302:686-687.
53. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
54. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113.
55. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004, 43:333-344.
56. Wang Y.J., Zhou H.D., Zhou X.F. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006, 11:931-938.
57. Kline A. Apolipoprotein E, amyloid-β clearance and therapeutic opportunities in Alzheimer's disease. Alzheimers Res Ther 2012, 4:32.
58. Wildsmith K.R., Holley M., Savage J.C., Skerrett R., Landreth G.E. Evidence for impaired amyloid beta clearance in Alzheimer's disease. Alzheimers Res Ther 2013, 5:33.
59. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
60. Zolezzi J.M., Bastias-Candia S., Santos M.J., Inestrosa N.C. Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-beta brain balance and the putative role of PPARs. Front Aging Neurosci 2014, 6:176.
61. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
62. Deacon R.M. Burrowing: a sensitive behavioural assay, tested in five species of laboratory rodents. Behav Brain Res 2009, 200:128-133.